Serum FGF 21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Summary: Objective: Fibroblast growth factor 21 (FGF 21) is an emerging metabolic regulator associated with glucose and lipid metabolism. However, previous studies of FGF 21 have been largely confounded by obesity, and data are limited for advanced outcomes such as coronary artery disease (CAD) and ectopic fat accumulation. We investigated the associations between serum FGF 21 concentrations and glucose/lipid metabolism, CAD, and pericardial fat deposition in subjects strictly matched for obesity parameters. Design, Patients and Measurements: We enrolled 189 patients who had undergone cardiac multidetector coronary computed tomography. We measured cardiometabolic parameters and serum FGF 21 levels within body mass index (BMI)‐matched groups. Correlations and linear regressions were analysed among serum FGF 21 levels, pericardial fat volumes and cardiometabolic parameters. Serum FGF 21 concentrations were compared in patients with and without diabetes, metabolic syndrome (MS) or CAD. Results: Serum FGF 21 concentrations were significantly higher in BMI‐matched patients with MS (107·2 ± 83·6 vs 82·1 ± 67·4 ng/l without MS, P < 0·05), but not among those with diabetes (84·3 ± 56·4 vs 96·3 ± 98·9 ng/l without diabetes, P = 0·300) or CAD (89·6 ± 65·8 vs 84·2 ± 83·1 ng/l without CAD, P = 0·633). Serum FGF 21 concentrations correlated positively with triglycerides, low‐density lipoprotein–cholesterol, insulin, HOMA‐IR and pericardial fat volume. They showed an independent association with pericardial fat volume (β = 0·111 ± 0·053, P < 0·05). Conclusions: Serum FGF 21 concentrations were significantly associated with lipid profiles, insulin resistance, pericardial fat volume and MS, independently of obesity, but not with overt CAD or diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Quantification of coronary artery calcium using ultrafast computed tomography
Agatston, A. S., Janowitz, W. R., Hildner, F. J., Zusmer, N. R., Viamonte, M., & Detrano, R. (1990) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(90)90282-t · Cited by 7,786
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Self-citationFibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
Zhang, X., Yeung, D. C. Y., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R. L. C., Chow, W.-S., Tso, A. W. K., Lam, K. S. L., et al. (2008) · Diabetes · doi:10.2337/db07-1476 · Cited by 908
Identification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738
Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904187106 · Cited by 704
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607
FGF21 is an Akt‐regulated myokine
Izumiya, Y., Bina, H. A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., & Walsh, K. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.021 · Cited by 415
Mraz, M., Bartlova, M., Lacinova, Z., Michalsky, D., Kasalicky, M., Haluzikova, D., Matoulek, M., Dostalova, I., Humenanska, V., & Haluzik, M. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03502.x · Cited by 279
FGF21 attenuates lipolysis in human adipocytes – A possible link to improved insulin sensitivity
Arner, P., Pettersson, A., Mitchell, P. J., Dunbar, J. D., Kharitonenkov, A., & Rydén, M. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.04.038 · Cited by 234
Chen, W.-W., Li, L., Yang, G.-Y., Li, K., Qi, X.-Y., Zhu, W., Tang, Y., Liu, H., & Boden, G. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-985148 · Cited by 186
Research works printed but not linked: 25
- 10.1210/jc.2011-1930 · DOI · Paper page
- 10.1016/j.diabres.2010.03.019 · DOI
- 10.1016/j.metabol.2010.02.016 · DOI
- 10.2337/dc08-1054 · DOI
- 10.1016/j.metabol.2010.03.018 · DOI
- 10.1016/j.jhep.2010.05.018 · DOI · Paper page
- 10.1210/jc.2010-1326 · DOI · Paper page
- 10.1371/journal.pone.0015534 · DOI · Paper page
- 10.1038/oby.2010.246 · DOI
- 10.1016/j.atherosclerosis.2008.10.041 · DOI
- 10.1161/01.CIR.51.4.5 · DOI · Paper page
- 10.1016/j.jacc.2006.02.064 · DOI · Paper page
- 10.1016/j.jacc.2010.10.036 · doi:10.1016/j.jacc.2010.10.036
- Region W.W.P., 2000, The Asia‐Pacific Perspective: redefining obesity and its treatment, International Obesity Task Force, 2, 15
- 10.1001/jama.285.19.2486 · DOI · Paper page
- 10.1002/jcp.20847 · DOI · Paper page
- 10.1016/j.mce.2011.05.003 · DOI
- 10.1002/dmrr.1177 · DOI · Paper page
- 10.1016/j.diabres.2012.01.004 · DOI
- 10.1210/jc.2012-1221 · DOI · Paper page
- 10.1371/journal.pone.0024895 · DOI · Paper page
- 10.1016/j.echo.2011.06.013 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.107.743062 · DOI · Paper page
- 10.1093/eurheartj/ehn573 · DOI · Paper page
- 10.1210/jc.2009-0436 · DOI · Paper page
Cited by
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
“suggested that plasma FGF21 levels are associated pericardial fat accumulation (462), which suggests that ectopic fat could be a source of FGF21 in metabolic disease.”
BackgroundRandomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
Staiger, H., Keuper, M., Berti, L., Hrabě de Angelis, M., & Häring, H.-U. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00016 · Cited by 270
Xu, P., Zhang, Y., Liu, Y., Yuan, Q., Song, L., Liu, M., Liu, Z., Yang, Y., Li, J., Li, D., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.11.012 · Cited by 97
Berti, L., Irmler, M., Zdichavsky, M., Meile, T., Böhm, A., Stefan, N., Fritsche, A., Beckers, J., Königsrainer, A., Häring, H.-U., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.04.002 · Cited by 73
Metadata
- Authors
- Lee, Y., Lim, S., Hong, E., Kim, J. H., Moon, M. K., Chun, E. J., Choi, S. I., Kim, Y., Park, Y. J., Park, K. S., Jang, H. C., & Choi, S. H.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2013-05-06
- Volume
- 80
- Issue
- 1
- Pages
- 57-64
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2004328158
- Cited by
- 84
- References
- 18
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.